PMID- 20634877
OWN - NLM
STAT- MEDLINE
DCOM- 20101006
LR  - 20231213
IS  - 1110-7251 (Electronic)
IS  - 1110-7243 (Print)
IS  - 1110-7243 (Linking)
VI  - 2010
DP  - 2010
TI  - The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune 
      response to pathogens and tumors.
PG  - 907092
LID - 10.1155/2010/907092 [doi]
LID - 907092
AB  - Human leukocyte antigen (HLA)-E is a nonclassical major histocompatibility 
      complex (MHC) class I molecule of limited sequence variability that is expressed 
      by most tissues albeit at low levels. HLA-E has been first described as the 
      ligand of CD94/NKG2 receptors expressed mainly by natural killer (NK) cells, thus 
      confining its role to the regulation of NK-cell function. However, recent 
      evidences obtained by our and other groups indicate that HLA-E complexed with 
      peptides can interact with alphabeta T-cell receptor (TCR) expressed on CD8(+) T 
      cells. Although, HLA-E displays a selective preference for nonameric peptides, 
      derived from the leader sequence of various HLA class I alleles, several reports 
      indicate that it can present also "noncanonical" peptides derived from both 
      stress-related and pathogen-associated proteins. Because HLA-E displays binding 
      specificity for innate CD94/NKG2 receptors, as well as all the features of an 
      antigen-presenting molecule, its role in both natural and acquired immune 
      responses has recently been re-evaluated.
FAU - Pietra, Gabriella
AU  - Pietra G
AD  - Dipartimento di Medicina Sperimentale and Centro di Eccellenza per le Ricerche 
      Biomediche, Universita degli Studi di Genova, 16132 Genova, Italy.
FAU - Romagnani, Chiara
AU  - Romagnani C
FAU - Manzini, Claudia
AU  - Manzini C
FAU - Moretta, Lorenzo
AU  - Moretta L
FAU - Mingari, Maria Cristina
AU  - Mingari MC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20100622
PL  - United States
TA  - J Biomed Biotechnol
JT  - Journal of biomedicine & biotechnology
JID - 101135740
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Peptides)
RN  - 0 (Receptors, Antigen, T-Cell, alpha-beta)
SB  - IM
MH  - Adaptive Immunity/*immunology
MH  - CD8-Positive T-Lymphocytes/*immunology
MH  - HLA Antigens/*immunology
MH  - Histocompatibility Antigens Class I/*immunology
MH  - Humans
MH  - Mycobacterium Infections/*immunology
MH  - Neoplasms/*immunology
MH  - Peptides/immunology
MH  - Receptors, Antigen, T-Cell, alpha-beta/immunology
MH  - Virus Diseases/*immunology
MH  - HLA-E Antigens
PMC - PMC2896910
EDAT- 2010/07/17 06:00
MHDA- 2010/10/07 06:00
PMCR- 2010/06/22
CRDT- 2010/07/17 06:00
PHST- 2010/01/14 00:00 [received]
PHST- 2010/05/04 00:00 [accepted]
PHST- 2010/07/17 06:00 [entrez]
PHST- 2010/07/17 06:00 [pubmed]
PHST- 2010/10/07 06:00 [medline]
PHST- 2010/06/22 00:00 [pmc-release]
AID - 10.1155/2010/907092 [doi]
PST - ppublish
SO  - J Biomed Biotechnol. 2010;2010:907092. doi: 10.1155/2010/907092. Epub 2010 Jun 
      22.